Octagam Wrongfull Death Lawyers:

Quote

Anonymous

Guest
http://www.prslegal.com/tag/octagam

RECALL OF OCTAGAM IGIV (Immune Globulin Intravenous) USED IN IMMUNODEFICIENCY INJECTIONS
Thursday, October 14th, 2010
On August 20, 2010, Octapharma USA Inc. recalled ALL lots of OCTAGAM (Immune Globulin Intravenous (human) 5% Liquid Preparation) currently in the United States. This voluntary market withdrawal was performed pending determination of the cause of strokes and death following use of this product. The FDA reported an unacceptable increase in the number of strokes during or following an injection of the defective lots of IGIV.

Octagam IGIV (Immune Globulin Intravenous) is a sterilized solution made from human plasma. It contains the antibodies to help the human body protect itself against infection from various diseases. Immune globulin is used to treat primary humoral immune deficiency (PI), such as congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome and severe combined immunodeficiencies, and to reduce the risk of infection in individuals with poorly functioning immune systems.

If you or someone you know has received this injection and suffered an injury or death as a result, please contact our firm for a free consultation and information regarding a potential claim. Pearson Randall, Gempeler, Schumacher & LaBore, P.A. is a law firm that practices in the areas of personal injury, consumer protection and national pharmaceutical litigation, and is working on issues relevant to this case. Contact Attorney Gale D. Pearson at gpearson@prslegal.com or call 612-767-7500 or toll free at 800-774-0757.

This website information is not intended to provide medical or legal advice, as each situation is different and specific factual information must be obtained before an attorney is able to assess the legal questions relevant to your situation. In addition to providing related information, this blog may also be considered an advertisement for legal services.


Pearson Randall, Gempeler, Schumacher & LaBore, P.A.

AGGRESSIVE AND COMPASSIONATE ATTORNEYS HELPING FAMILIES RECOVER

FROM BAD ACCIDENTS, BAD DRUGS AND BAD PRODUCTS.

612-767-7500 or 800-774-0757 (toll free)
 






Here's aother one:

http://www.finzfirm.com/drugs/Octagam_Injury_Lawyer/


'If the safety don't fit, the production must quit.'


...What Are The Side Effects Of Octagam?

The symptoms of Octagam side effects caused by thromboembolic events (which occur when a blood clot, or thrombosis, detaches from where it is affixed, passed through the blood-stream, and clogs a blood vessel) include:

Symptoms of peripheral embolism:

Paresthesias;
Tingling;
Numbness;
Pain;
Weakness; and,

Weak pulse.
Symptoms of brain embolism:

Sudden numbness or weakness of the face, arm or leg, especially on one side of the body;
Sudden confusion, trouble speaking or understanding;
Sudden trouble seeing in one or both eyes;
Sudden trouble walking, dizziness, loss of balance or coordination; and,
Sudden, severe headache with no known cause.

Symptoms of kidney embolism:

Kidney failure; and,

High blood pressure.
Symptoms of gastrointestinal embolism:

Severe abdominal pain;
Nausea;
Vomiting; and,
Shock.
These symptoms are, in some patients permanent, thereby robbing them of their quality of lief in some instances, and even potentially causing death in others.

What Is The Mechanism For Injury; and, Which Lots Are Effected?

Octagam has been causally linked to thromboembolic events, and the results of those thromboembolic events can cause significant damage to those who have been administered Octagam.

Legal Help for Octagam Injury Victims

To further understand your rights, consult with an attorney who is knowledgeable regarding the dangerous side effects of Octagam.

If you, a family member, or friend have suffered due to the use of Octagam, please contact a Octagam Injury Attorney at the Finz firm today at (855) TOP-FIRM to speak with an experienced attorney now or fill out the Free Octagam Injury Case Evaluation form.
 


















FDA added Octagam to watchlist February of 2011..

http://www.pharmainfo.net/og/pharmindia/fda-adds-13-drugs-watch-list

FEB 08 2011:

FDA adds 13 drugs to watch list
Submitted by s.k.r.sowmya on Thu, 02/10/2011 - 06:15
February 8, 2011 — The US Food and Drug Administration (FDA) has released its latest list of drugs to monitor based on potential signs of serious risks or new safety information identified in the agency's Adverse Event Reporting System (AERS).
The quarterly watch list consists of 13 medications that treat a wide range of conditions, including cough, angina, diabetes, cancer, and bipolar disorder.
The agency is studying the 13 drugs to determine whether they are causally linked to the possible risks reported through AERS from July 1, 2010, through September 30, 2010. In the meantime, the FDA considers them pharmacologically innocent until proven guilty. Physicians should not stop prescribing these drugs, therefore, nor should patients stop taking them, according to the agency.
There are some exceptions to this suspended judgment approach, however. One involves immune globulin G intravenous (human) 5% liquid preparation (Octagam, Octapharma USA), used to treat primary immunodeficiency diseases. At the FDA's request, the manufacturer withdrew all lots of the biologic from the market last September while it investigated reports of blood clots and embolisms.
Similarly, that month Amgen recalled certain lots of epoetin alfa (Epogen and Procrit), an anemia therapy, because they may have contained extremely thin glass flakes called lamellae.
Potential Signals of Serious Risks/New Safety Information Identified by AERS, Third Quarter 2010
Product Name Potential Signal of a Serious Risk/New Safety Information
Benzonatate (Tessalon, Pfizer) Death from accidental ingestion in children
Dronedarone hydrochloride (Multaq, Sanofi-Aventis) Drug interaction with warfarin (increased anticoagulant effect)
Epoetin alfa (Epogen/Procrit, Amgen) Possible contamination with shards from glass vial
Gemcitabine hydrochloride (Gemzar, Lilly) Veno-occlusive liver disease
Lanreotide acetate (Somatuline Depot, Beaufour Ipsen) Pancreatitis, hemorrhagic and necrotizing pancreatitis
Lanthanum carbonate (Fosrenol, Shire) Swallowing complications, gastrointestinal obstruction (attributed to tablet hardness)
Levetiracetam (Keppra, UCB Inc) Stevens-Johnson's syndrome, toxic epidermal necrolysis
Lithium citrate (Eskalith and Lithobid, Noven) Brugada syndrome
Lopinavir/Ritonavir oral solution (Kaletra, Abbott) Serious adverse events in neonates
Immune globulin G intravenous (human) 5% liquid preparation (Octagam, Octapharma USA) Thromboembolic adverse events
Pioglitazone HCl (Actos, Takeda) Rhabdomyolysis
Ranolazine (Ranexa, Gilead) Drug interaction with statins (rhabdomyolysis)
Sodium oxybate (Xyrem, Jazz) Death
The current list of drugs with potential safety issues is available on the FDA's Web site.
Also available are the AERS-generated watch lists for drugs covering previous time periods.

Information available at http://www.medscape.com/viewarticle/737056?sssdmh=dm1.664957&src=nldne
 






Octapharma has finally reached the pinnacle of it's success curve. Wolfgang needs to send his sons into retirement and finally hire men and women of great experience and intellect.
Tobias and Frederick are not stooges, but here again they are not biological production/sales/marketing/stakeholder/sharholder experts. So knows the EU and American Regulators. Get real Wolfgang. Frederick is a universal playboy and a man not at all interested in improving shareholder value. On the other hand Tobias is an honest and sincere fellow wanting nothing but the best for the OctaPharma family. Wolfgang you've purged the company of your head of plasma collections, manufacturing and good Ole Barbara. What's left?
 






Who's left? ha! Corruption abounds both in operations and quality - top down. Death from within. You have no idea! Send internal Octapharma auditors from the E.U. to the U.S. collection centers, the U.S. corporate staff is corrupt. Bring a large suitcase, you will be here for a while. Look at the training files, the product/freezer documentation, DMS QC records, collection exception documentation, non-conformance reporting from the top down, supply lot control and documentation, temperature documentation, RED CELL LOSS Documentation, Medical Incident documentation, deadlines for all, DMS records VS paper records. Clean up your house before it's done for you.
 


















Top Bottom
Back
Quote